Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes

Author(s): Giada Pallini and Emmanuel A. Tsochatzis*

Volume 27, Issue 27, 2021

Published on: 27 January, 2021

Page: [3036 - 3046] Pages: 11

DOI: 10.2174/1381612827666210127120748

Price: $65

Abstract

The global prevalence of NAFLD is estimated to be over 25% and it is already the leading cause of chronic liver disease in industrialized countries, as a consequence of the spread of obesity and metabolic syndrome. The prognosis of NAFLD is generally benign in the absence of fibrosis, but liver fibrosis rapidly progresses in 20% of the cases and can lead to cirrhosis and/or HCC. This review focuses on non-invasive fibrosis testing strategies for patients with NAFLD in order to increase the efficiency and effectiveness of diagnosis and care, regulating secondary care referral fluxes. An integrated management plan between primary care and secondary care with a defined algorithm of non-invasive testing to stratify the risk of NAFLD fibrosis is indispensable to increase the early diagnosis of fibrosis but also decrease unnecessary referrals.

Keywords: Steatohepatitis, non-invasive fibrosis tests, primary care, FIB-4, ELF, cirrhosis.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy